tradmap

CI Financials Cigna

10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 11.4% per year over the past 5 years.
  • Net income has grown slower than revenue (7.4% vs 11.4% per year).
  • Operating margin has contracted, at 3.3% in the latest year.
  • Free cash flow has grown 33.3% per year over the past 5 years.

Shareholder returns

  • Dividends have been paid for 7 consecutive years, consuming 27.0% of earnings.
  • The dividend has grown 154.8% per year over the past 5 years.
Revenue & net income
$0 $137B $275B 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 47% 94% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
0% 7% 14% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
ROEROA
Free cash flow (CFO − capex)
$0 $4B $8B 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $21B $41B 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$26B -$1B $24B $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $274.9B $6.0B 21.8% 3.3% 14.3% 3.8% — — $7.7B
2024 $247.1B $3.4B 26.1% 3.8% 8.4% 2.2% — — $7.5B
2023 $195.3B $5.2B 31.5% 4.4% 11.2% 3.4% — — $7.8B
2022 $180.5B — 30.8% 4.7% 0.0% 0.0% — — $5.9B
2021 $174.1B — 32.5% 4.6% 0.0% 0.0% — — $5.1B
2020 $160.4B — 35.5% 5.1% 0.0% 0.0% — — $10.2B
2019 $153.6B — 36.4% 5.3% 0.0% 0.0% $8.4B — $4.6B
2018 $48.6B — 90.1% 8.6% 0.0% 0.0% $3.2B $41.0B $3.9B
2017 $41.8B — 94.1% 9.4% 0.0% 0.0% $3.6B — $3.0B
2016 $39.8B — 93.8% 7.8% — — $3.6B — $3.2B

Valuation over time

How the market has priced CI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 13.0 26.0 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 0.2 0.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 1.2 2.4 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is CI growing its revenue and profit?

Over the past 5 years, Cigna's revenue has grown 11.4% per year, and net income grown 7.4% per year. These are computed facts, not advice.

How much debt does CI have?

As of FY2025, Cigna reported — of total debt against $7.7B of cash.

What is CI's profit margin?

In FY2025, gross margin was 21.8%, operating margin 3.3%, and net margin 2.2%.

What is CI's P/E ratio?

Cigna's P/E (TTM) is 13.09 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the CI stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 13.1× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.